|
 |
AbciximabThis page contains recent news articles, when available, and an overview of Abciximab but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Abciximab (when available) Used for the treatment of myocardial infarction and the prevention of platelet aggregation. Abciximab inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules to GPIIb/IIIa receptor sites on activated platelets. For treatment of myocardial infarction, adjunct to percutaneous coronory intervention, unstable angina Mechanism Of Action: Abciximab binds to the intact platelet GPIIb/IIIa receptor, which is a member of the integrin family of adhesion receptors and the major platelet surface receptor involved in platelet aggregation. This binding is thought to involve steric hindrance and/or conformational alterations which block access of large molecules to the receptor rather than direct interaction with the RGD (arginine-glycine-aspartic acid) binding site of GPlIb/IIIa. News Articles on Abciximab Atrium Medical Corporation Announces Release of the Final Results of the ... - Nov 5, 2009 The final results demonstrated that super selective local intracoronary infusion of an anti-platelet medication known as abciximab* through the Atrium® ... Market Wire (press release) Ранната терапиÑ? Ñ? abciximab дава ползи при виÑ?окориÑ?кови STEMI пациенти 09 ... - Nov 9, 2009 Прилагането на abciximab при виÑ?окориÑ?кови пациенти Ñ?ÑŠÑ? ST-елевационен инфаркт на миокарда (STEMI) преди транÑ?фера за перкутанна коронарна интервенциÑ? (PCI) ... DoctorBG.com ADenosine Administration during and after Primary percutaneous ... - Aug 9, 2009 The majority of the patients (about 92.5%) received abciximab. There was no difference in the incidence of residual ST-segment deviation <0.2 mV between the Cardiosource Thromboelastometry-guided administration of fibrinogen concentrate ... - Aug 20, 2009 Different effects of abciximab and cytochalasin D on clot strength in thrombelastography. J Thromb Haemost 2004;2:147-153.[Medline] Reinhofer M, Brauer M, The Journal of Thoracic and Cardiovascular Surgery Featured Clinical Trials To Be Presented At Transcatheter ... - Aug 21, 2009 Cath Lab-Initiated Intravenous Abciximab in Patients with STEMI Patrick Ohlmann, MD, PhD NO REFLOW: A Prospective Randomized Trial of Intracoronary vs. Medical News Today (press release) Accumetrics Gunning To Be the Medical Diagnostics Standard for ... - Jun 19, 2009 Accumetrics also offers other assays for measuring the effectiveness of other specific drugs on platelets, including aspirin, abciximab (ReoPro), Xconomy TRANSFER AMI published: Finding the optimal window for PCI postlysis - Jun 25, 2009 They write, "Our findings are similar to those seen in the recent CARESS-in-AMI trial, in which a half-dose of reteplase combined with abciximab was used as TheHeart.Org Low-Molecular-Weight Heparin as an Adjunct to Thrombolysis in ST ... - Jun 22, 2009 Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial Archives of Internal Medicine IIb-IIIa 糖蛋白抑制剂在å?»ç¼ºè¡€å¤§é¼ 部分截肢术模型ä¸çš„作用 - Jun 25, 2009 ...医å¦ç©ºé—´ï¼ˆMEDcyber.com）6月26日消æ?¯â€”近期《Journal of Reconstructive Microsurgery》上å?‘è¡¨ä¸€ç¯‡æ–‡ç« è®¤ä¸ºè¡€å°?æ?¿ç³–蛋白IIb/IIIa抑制物Abciximabå’ŒTirofibanå?¯ä»¥å¢žå¼º 医学空间 Asma e BPCO: potenziale ruolo terapeutico degli antagonisti dell ... - Jun 23, 2009 Abciximab; ReoPro ), dell'integrina alfaLbeta2 ( Efalizumab; Raptiva ), e dell'integrina alfa4beta1 ( Natalizumab, Tysabri ), nel trattamento, XagenaSalute ABOARD: Immediate cath no better than next-day intervention for ... - Mar 30, 2009 ...and 60% of patients on abciximab. He suggested therefore that the study was more a test of "facilitated PCI" than primary PCI for NSTE-ACS patients. TheHeart.Org Predictors of Stent Thrombosis After Primary Angioplasty in Acute ... - Mar 29, 2009 There was no significant difference in the 1-year stent thrombosis rate within the heparin plus IIb/IIIa inhibitor group between eptifibatide and abciximab Cardiosource AGIR-2 et ON TIME-2 à un an apportent des précisions sur l'utilité ... - Mar 30, 2009 Un essai avec aspiration du thrombus suivi d'une injection intra-coronaire d'abciximab devrait prochainement débuter, at-il précisé. theheart.org/fr ABOARD prouve que les SCA non ST peuvent être revascularisés le ... - Apr 2, 2009 Tous les patients angioplastiés recevaient de l'abciximab. Le suivi est de un mois. Les investigateurs ont choisi comme marqueur optimal immédiat de la theheart.org/fr Une analyse poussée d'HORIZONS AMI détaille les facteurs de risque ... - Mar 30, 2009 Le type d'anti-GPII b/IIIa — eptifibatide ou abciximab — utilisé avec l'héparine ne l'influe pas non plus (3,6 vs 2,8 %, NS). En revanche l'utilisation, theheart.org/fr 2014ë…„ 3ê°œ í•í˜ˆì „ì œ 블ë¡?버스터 - Apr 1, 2009 ...eptifibatide)ì?´ ìž‘ë…„ 3ì–µ1400만달러ì—?ì„œ 2014ë…„ 2ì–µ6500만달러로, â€˜ë ˆì˜¤í”„ë¡œâ€™(ReoPro, abciximab)ê°€ 2ì–µ5600만달러ì—?ì„œ 1ì–µ9900만달러로 다소 하ë?½ì?´ ì „ë§?ë?œë‹¤. 디지틀보사 BRIEF-PCI publié : mieux vaut perfuser l'eptifibatide en 2 heures ... - 18 Mar 2009 L'étude d'O Bertrand avait déjà suggéré des résultats similaires en montrant la non-infériorité d'un bolus d'abciximab versus 12 heures de perfusion dans theheart.org/fr Brief Infusion of Eptifibatide Following Percutaneous Coronary ... - Mar 2, 2009 This trial should be placed in the context of the ISAR-REACT trial, which showed that a glycoprotein IIb/IIIa inhibitor (abciximab) is not beneficial in Cardiosource Pre-Procedural C-Reactive Protein Levels and Clinical Outcomes ... - Jan 27, 2009 Abciximab therapy does not confer any particular beneficial effect in patients with a higher inflammatory burden. Perspective: CRP has been consistently Cardiosource, What's the evidence for glycoprotein IIb/IIIa inhibitors? - Jan 21, 2009 Most of the research we found looked at the drug abciximab. We looked at two big, high-quality studies comparing clot-busting drugs (with or without extra guardian.co.uk, What treatments work for unstable angina? - Jan 21, 2009 There are three of them: abciximab (brand name ReoPro), eptifibatide (Integrilin) and tirofiban (Aggrastat). More... Direct thrombin inhibitors: These drugs guardian.co.uk, Thrombectomy With Export Catheter in Infarct-Related Artery During ... - Jan 19, 2009 Patients received aspirin 300 mg, clopidogrel 300 mg, intravenous heparin, and abciximab. Overall, 175 patients were randomized. Cardiosource, Due nuovi studi sul trattamento dell'infarto miocardico - Jan 13, 2009 Nel primo [1] quasi 2500 pazienti sono stati trattati entro 6 ore dall'inizio dei sintomi con abciximab + metà dose di reteplase e successiva PCI (PCI Pillole.org, Eptifibatide and abciximab inhibit insulin-induced focal adhesion ... - Dec 23, 2008 The use of abciximab (c7E3 Fab) or eptifibatide improves clinical outcomes in diabetics undergoing percutaneous coronary intervention. 7thSpace Interactive (press release), Author Disclosure: Consultant/Consulting Fees/Honoraria: Boston ... - Dec 15, 2008 The goal of the trial was to evaluate routine treatment with the glycoprotein (GP) IIb/IIIa inhibitor abciximab in addition to standard therapy during Cardiosource, Clinical Trial: No - 21 Nov 2008 ...and platelet glycoprotein IIb/IIIa receptor antagonist (preferably abciximab). b. Fondaparinux should not be used in patients undergoing primary PCI. Cardiosource, Pillen mit Vergangenheit - 21 Nov 2008 Jahren in großen Studien getestet wurden, wie zum Beispiel das HIV-Mittel Indinavir oder Abciximab, ein Mittel zur Verhinderung von Gefäßverschlüssen. jetzt.de, Early Abciximab Administration Before Primary Percutaneous ... - Oct 29, 2008 By Marvin Ross TORONTO -- October 29, 2008 -- The rapid administration of abciximab in regional hospitals before patients are transferred for primary DG News BUYINS.NET: (JNJ) SqueezeTrigger Price is $63.343. There is ... - Oct 29, 2008 ...for the treatment of acute myocardial infarction to improve blood flow to the heart, and REOPRO (abciximab) for the treatment of acute cardiac disease. Trading Markets (press release), Normativa. BOE - Nov 3, 2008 ...por la que se publica adjudicación definitiva de suministro de Gemcitabina, Abciximab, Drotrecogina Alfa Pemetrexed y Teriparatida. Expediente CCA. ecodiario, Combined Abciximab Reteplase Stent Study in Acute Myocardial ... Aug 31, 2008 Among high-risk STEMI patients presenting to a center without PCI facilities who receive heparin, half-dose reteplase, and abciximab, immediate transfer forCardiosource, Pre-Hospital Treatment On The Way To Percutaneous Coronary ... Sep 2, 2008 Most of the studies on the role of GPIIb/IIIa antagonists in STEMI have focused on abciximab rather than on the lower molecular weight agents: tirofiban andMedical News Today (press release), Mortality closely tied to major bleeds at primary PCI, HORIZONS ... Sep 12, 2008 ...inhibitor (either abciximab or eptifibatide) on top of aspirin and clopidogrel; all patients underwent angiography and then were triaged to primary PCI,TheHeart.Org, Prehospital Initiation of Tirofiban in Patients With ST-Elevation ... Aug 21, 2008 The results of this study are discordant with the BRAVE 3 trial in which abciximab did not differ from placebo when used on top of high-dose clopidogrel inCardiosource, Percutaneous Coronary Intervention Not Inferior to Bypass Grafting ... Sep 3, 2008 ...left main stem disease, cardiogenic shock, recent ST-segment elevation MI, or contradictions to abciximab, aspirin, and clopidogrel use.DG News Tailoring Treatment with Tirofiban in patients showing Resistance ... Sep 2, 2008 ...the ISAR-REACT trial documented that a glycoprotein IIb/IIIa inhibitor (abciximab) is not required among stable patients pretreated with clopidogrelCardiosource, Coronary Artery Revascularization in Diabetes Trial (CARDia ... Sep 1, 2008 All patients in the PCI arm received aspirin, clopidogrel, and abciximab. A total of 510 patients were randomized, 254 to CABG and 256 to PCI.Cardiosource, The Cost-Effectiveness of Thrombolysis Administered By Paramedics* Aug 28, 2008 Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardialRedOrbit, On-TIME 2 in Print: Acute STEMI Gains with Prehospital Triple ... Aug 15, 2008 Studies of prehospital GP IIb/IIIa inhibition in STEMI, usually with abciximab (ReoPro, Centocor/Eli Lilly), have been conducted primarily in Europe,Medscape (subscription) Le suivi à 1 an de CARESS-AMI conforte le bénéfice du transfert ... Sep 2, 2008 ...rétéplase demi-dose plus abciximab, mieux vaut adresser le patient immédiatement sur un site d'angioplastie qu'attendre pour voir ce qui se passe [1].TheHeart.Org, MI in Pregnancy: Numbers Increasing but Management Improving - Jul 10, 2008 Glycoprotein IIb/IIIa inhibitors, including eptifibatide and tirofiban (category B) and abciximab (category C), might warrant cesarean delivery. Medscape (subscription) Porównanie dowieÅ„cowego podania dawki nasycajÄ…cej abciksimabu z ... - Aug 4, 2008 Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous Polskie Towarzystwo Kardiologiczne, Abciximab bolus at primary PCI: IC route may limit infarct size - Jun 20, 2008 Leipzig and Berlin, Germany - In the setting of acute ST-elevation MI (STEMI) treated with PCI, giving the initial bolus of abciximab (ReoPro, TheHeart.Org, Manual Clot Removal After Heart Attack Improves Outcomes - Jun 6, 2008 All patients got standard treatment with heparin, aspirin, a 600-mg loading dose of clopidogrel (Plavix), and abciximab (ReoPro). MedPage Today, Mixed Results for Anti-Clotting Drugs in Heart Attacks - May 21, 2008 So cardiologists have been testing the value of two drugs -- reteplase, which dissolves clots, and abciximab, which prevents their formation -- for people U.S. News & World Report, Study touts new drug for use in angioplasty - May 21, 2008 A third of them were given only angioplasty; a third received a clot dissolver called reteplase plus the clot-preventing drug abciximab before they Los Angeles Times, Focus on improving time to PCI, not on "facilitating" with drugs ... - May 22, 2008 Boston, MA - Full results from the FINESSE trial, showing no advantage of early abciximab or a half-dose lytic plus abciximab combination over PCI alone in TheHeart.Org, Facilitated PCI in Patients with ST-Elevation Myocardial Infarction - May 21, 2008 All patients received unfractionated heparin or enoxaparin before PCI and a 12-hour infusion of abciximab after PCI. The primary end point was the composite New England Journal of Medicine (subscription), Early Drug Treatment Before PCI Does Not Lead to Better Outcomes - May 21, 2008 The participants were randomized to early treatment with abciximab plus half-dose reteplase (828) or abciximab alone (818) or to standard intervention MedPage Today, Pharmacologic reperfusion before PCI doesn't improve STEMI outcome - May 22, 2008 Early reperfusion using abciximab plus reteplase prior to percutaneous coronary intervention (PCI) does not improve outcomes in patients with ST-segment Medicexchange, Bivalirudin Beats Heparin and Glycoprotein IIb/IIIa Inhibitors in ... - May 21, 2008 In addition to dual antiplatelet therapy with aspirin and clopidogrel (Plavix), patients were randomized to unfractionated heparin plus abciximab (ReoPro) MedPage Today, BRAVE-3 Questions Value of Abciximab in PCI for Heart Attack - Mar 30, 2008 The BRAVE-3 study is the first to test the influence of high-dose clopidogrel on the value of abciximab exclusively in patients with ST-elevation myocardial FOXBusiness Tirofiban Is as Effective as Abciximab for Lowering ST-Segment ... - Apr 2, 2008 By Bruce Sylvester CHICAGO -- April 2, 2008 -- Treatment with tirofiban resulted in noninferior ST-segment resolution compared with abciximab among patients DG News Abciximab Fails to Add Benefit in Acute Myocardial Infarction for ... - Apr 1, 2008 By Ed Susman CHICAGO -- April 1, 2008 -- Researchers suggested that abciximab or other glycoprotein IIB/IIIA inhibitors are unnecessary if patients with DG News High-dose tirofiban as effective as abciximab in reducing ST ... - Mar 31, 2008 At least 50 percent recovery from ST-elevation occurred in 85.3 percent and 83.6 percent of patients in the tirofiban and abciximab groups, EurekAlert (press release), ACC: Both Tirofiban and Abciximab Work - Mar 30, 2008 By Peggy Peck, Executive Editor, MedPage Today CHICAGO, March 30 -- High-dose bolus tirofiban (Aggrastat) was as effective as abciximab (ReoPro) infusion in MedPage Today, Medicure Comments on Positive AGGRASTAT Results Presented at the ... - Apr 3, 2008 7.5% (p equals 0.55) between tirofiban and abciximab. The 984-patient ON-TIME 2 study showed that treatment with tirofiban in addition to aspirin, CNNMoney.com Drug-Eluting Stents Outperform Bare Stents in Heart Attack - Mar 30, 2008 ..."These findings may provide a robust scientific rationale for high-dose tirofiban as an alternative to abciximab in patients with STEMI," said Marco FOXBusiness An update from the American College of Cardiology 2008 Scientific ... - Apr 16, 2008 The first, the Comparison of Angioplasty With Infusion of Tirofiban or Abciximab and With Implantation of Sirolimus-Eluting or Uncoated Stents for the TheHeart.Org, Comparison Of Anticoagulants For Angioplasty Show Similar Outcomes - Mar 30, 2008 30, 2008) — In a comparison of anticoagulants and stents for use with angioplasty following a heart attack, the anticoagulants abciximab and tirofiban had Science Daily (press release) Anticoagulant Drugs Had Similar Outcomes After Angioplasty - Mar 30, 2008 SUNDAY, March 30 (HealthDay News) -- In heart attack patients who had angioplasty, the anticoagulant drugs abciximab and tirofiban produced similar outcomes U.S. News & World Report, Tirofiban in STEMI: Two new randomized clinical trials demonstrate ... - Apr 11, 2008 Complimentary strategies for reducing MACE in patients undergoing PCI for STEMI include abciximab infusion and uncoated stent implantation. TheHeart.Org, BRAVE-3: Drop GP IIb/IIIa inhibitors in STEMI - Mar 30, 2008 Chicago, IL - Use of the GP IIb/IIIa inhibitor abciximab in acute ST-elevation MI (STEMI) patients undergoing PCI after pretreatment with a loading dose of TheHeart.Org, MULTISTRATEGY: Tirofiban and sirolimus stents in primary PCI - Mar 30, 2008 Chicago, IL - High-dose tirofiban was "noninferior" to abciximab in terms of resolution of ST-segment elevation at 90 minutes in STEMI patients undergoing TheHeart.Org, Drug-Releasing Stent Better Than Uncoated Stent For Angioplasty - Mar 30, 2008 The researchers were interested in testing if using tirofiban instead of abciximab could results in similar benefits as well as clinical and economic Medical News Today, Tirofiban can be used to treat STEMI, study shows - Apr 1, 2008 High doses of the drug tirofiban is as effective as abciximab in reducing ST-segment elevation in patients with ST-elevation myocardial infarction (STEMI), Nursing Times, Encouraging News and Discoveries in the Use of Drug-Eluting Stents - Apr 10, 2008 Dr. Valgimgli and associates studied patients who received anticoagulants Abciximab and Tirofiban within 90 minutes of angioplasty procedure. DOTmed.com (press release), ACC: Drug-Eluting Stent Safety for Acute MI Seen in Real World ... - Mar 31, 2008 ...improved major cardiovascular adverse events over abciximab (ReoPro) and heparin (See: HORIZONS AMI Verdict: Bivalirudin (Angiomax) a Winner). MedPage Today, ACC: Manual Clot Removal Boosts Clinical Benefit of PCI in Acute MI - Mar 30, 2008 All patients got standard treatment with heparin, aspirin, a 600-mg loading dose of clopidogrel (Plavix), and abciximab (ReoPro). MedPage Today, Brand Names/Synonyms: Abciximab is also known by the following brand names and/or synonyms: ReoPro; 7E3 antibody; antiGPIIBIIIa; ReoPro (Centocor) Drug Category: Abciximab is categorized under the following by the FDA: Anticoagulants; Antiplatelet Agents Dosage Forms: Not Available Absorption: Not Available Interactions: Not Available Chemical IUPAC Name: Chimeric human-murine (anti CD41) 7E3 antibody. |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |
